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ABSTRACT
Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of 
nuchal translucency (NT) measurement, Fetal Heart Rate (FHR), double test, quantitative [Ductus Venosus (DV) Pulsatility 
Index for Veins (PIV)] and qualitative (the A-wave assessment) blood flow evaluation in the DV.
Material and methods: The study was performed in 7296 singleton pregnancies. In each fetus NT, FHR, DV-PIV were 
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined 
screening investigated. Additional doppler ultrasound markers such as abnormal a-wave in Ductus Venosus and Pusatility 
Index for Veins of Ductus Venosus were and their impact on Trisomies 18 and 13 screening were examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy 
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 90.2% and FPR was 
6%. Detection Rates of examined chromosomal abnormalities using contingent screening were: 92.1% using DV abnormal 
a-wave and 94.84% using DV-PIV. FPR’s for booths parameters 5.8% and 5.4% respectively.
Conclusions: Quantitative analysis of the flow — assessment of DV-PIV in the first trimester significantly influences the 
improvement of screening values focusing on Trisomy 18 and 13 detection.
Key words: Combined test trisomy 18 trisomy 13; first trimester nuchal translucency thickness; ductus venosus pulsatility 
index for veins; serum free β-hcg; pregnancy-associated plasma protein A 
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INTRODUCTION
Congenital anomalies and chromosomal defects are 
most common causes of neonatal mortality and morbidity. 
On that account, in the period of the last dozen years we 
have been observing the development of scientific research 
that would enable the early diagnosis of defects and would 
let provide these defects possible treatment [1]. 
First trimester screening for chromosomal defects is 
based on ultrasound examination with assessment of NT 
(Nuchal Translucency) and “double test” based on free 
β-human Chorionic Gonadotropin (hCG) and Pregnancy 
Associates Plasma Protein-A (PAPP-A ) concentrations in ma-
ternal blood expressed in Multiplies of the Median (MoM).
The essential ultrasound screening performed be-
tween the 11 + 0 and 13 + 6 weeks. [corresponding to 
Crown-Rump Length (CRL) between 45–84 mm] is based 
on the assessment markers of chromosomal defects with 
NT being the first. Additional markers are Nasal Bone (NB), 
Tricuspid Regurgitation (TR) and ductus venosus flow as-
sessment (DV). The latter is more and more often used in 
screening [2–4]. 
In 65% of fetuses with Down syndrome and 55% of 
fetuses with Trisomy 18 or 13, the reversed A-wave, cor-
responding to atrial contraction, is detected in DV (it is the 
qualitative assessment of the flow) [5]. Additionally, Pulsa-
tility Index for Veins (PIV), which provides the quantitative 
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evaluation, is also taken into consideration. The average 
value of DV-PIV is 0.94 (range from 0,53 to 1.99) [6]. 
In first trimester screening for the most common 
chromosomal defects in general population for trisomy 
21, 18 and 13, Fetal Medicine Foundation has developed 
the algorithm based on maternal age, CRL, NT, fetal heart 
rate (FHR) free β-hCG and PAPP-A. This screening strategy 
provides the Detection Rate (DR) of approximately 90% with 
the False Positive Rate (FPR) of approximately 3–5% [7]. If 
the assessment of DV flow is added, the test DR increases 
to 96% for Trisomy 21, to 92% for Trisomy 18 and to 100% 
for Trisomy 13. FPR for all is 3% [8].
Non-invasive prenatal screening focuses on identify-
ing pregnant women who are at high risk of chromosomal 
defects and in whom invasive testing would be justified. [9]
Objectives
The objective of the paper is the suitability assessment 
of screening for Trisomy 18 and 13 on the basis of NT meas-
urement, double test, quantitative (DV-PIV) and qualitative 
(the A-wave assessment) blood flow evaluation in the DV. 
MATERIAL AND METHODS
In total, 7466 fetuses in singleton pregnancies were 
examined. It should be stressed that the fetuses with other 
syndromes (Trisomy 21 — 83 , Turner Syndrome — 12, 
Tetraploidy — 4, Unbalanced translocations — 5 cases re-
spectively) and structural defects with normal karyotype, 
such as: heart defects — Hypoplastic Left Heart Syndrome 
— 12 , Atrioventricular Septal Defects - 8, Tetralogy of Fallot 
— 4 and Transposition of the Great Arteries — 2 cases were 
excluded from the research. Other structural fetal defects 
excluding fetuses from the study were: Fetal Hydrops — 13, 
Spina bifida — 10, Hydrocephalus — 6, Palate or upper lips 
cleft — 6, Omphalocele — 3 and Gastroschisis — 2 cas-
es. The study was performed in 7296 singleton pregnancies 
scanned in the Department of Obstetrics and Gynecology 
in Ruda Śląska and in Outpatient Clinic “GENOM” in Ruda 
Slaska. All ultrasound examinations at 110 a 13+6 weeks were 
performed according recommendations of Polish Gyneco-
logical Society (PTG - Polskie Towarzystwo Ginekologiczne) 
and Fetal Medicine Foundation (FMF)., Assessed parameters 
were: CRL, FHR, NT and DV-PIV were measured and the quali-
tative assessment of A-wave in DV was performed according 
to FMF rules [9]. In all cases CRL was between 45–84 mm.
For the PIV the 95th percentile was designated and it was 
taken into consideration within the quantitative analysis. 
Specialists in obstetrics and gynecology with valid of 
FMF and PTG certificates performed all scans using GE Vo-
luson Expert 730 or GE Voluson E8 ultrasound machines. 
Directly after the scan, all patients had their blood 
taken for double test. Maternal blood was tested using the 
FMF-certified Delfia Express Perkin–Elmer and the concen-
tration of the free β-hCG and PAPP-A were converted to 
MoMs and then the risk of trisomies was calculated by the 
FMF certified ASTRAIA software.
Patients in high risk for chromosomal defects (≥ 1/300), 
were offered amniocentesis for karyotyping (total amount 
of amniocentesis were 337 cases, whereas in 100 cases, 
parents did not consent to invasive test) . In patients, who 
declined invasive testing, postnatal follow up was per-
formed. Pregnancy outcome was collected in all cases by 
the questionnaires (filled and returned by the patients) and 
the medical history of newborns. The neonatal phenotype 
was also evaluated. In the cases with no developmental 
defects and congenial diseases, the newborns were qualified 
as healthy. In all cases of increased NT in the first trimester 
and/or development defects suspected on prenatal ultra-
sound, a newborn baby underwent a detailed examination 
by a neonatologist, pediatric cardiologist and a geneticist. 
Karyotyping was performed in all phenotypically abnormal 
newborns. For the purpose of this paper, only the phenotypi-
cally normal newborns (they were approved as healthy) and 
fetuses that were detected Trisomy 13 and 18 were calcu-
lated. In this way two groups were obtained: 7239 normal 
neonates and 57 cases of Trisomies 18 and 13 respectively.
Statistical analysis: The Statplus Mac Ver 5 and Wizard 
Version 1.6.8 statistical packages were used to analyze the 
data. The Shapiro-Wilk test was applied to assess these re-
sults distribution. After ascertaining differences in relation 
to normal results distribution, the Mann Whitney’s U test 
was applied to conduct further calculations. To analyze 
qualitative parameters, the Chi2 test was used. The diag-
nostic threshold value for particular measurements was 
determined on the basis of the ROC (Receiver Operating 
Curve). Sensitivity and specificity were calculated for each 
threshold value. In all tests, the p level of probability, which 
was lower than the assumed level of significance (p < 0.05), 
was adopted as the level of differences statistical signifi-
cance. DR and FPR for separate configurations of markers 
of the first pregnancy trimester: NT, MA, BC and FHR have 
been compared. 
RESULTS
Two groups of patients were compared. The group of 
healthy women was constituted by 7239 patients whose 
fetuses were not detected chromosomal aberrations or any 
other development defects. The group of diseased wom-
en included 57 patients whose fetuses had Trisomy 13 or 
18 confirmed on the basis of the karyotype examination. 
The medians of outcomes of all examined and assessed 
parameters in both groups of healthy and diseased patients 
were observed and compared by Mann Whitney’s U test 
(Tab. 1).
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The test with the lowest DR factor was characterized. It 
took into consideration the combination of the following 
basic markers: NT, MA, BC and FHR. In this case this factor 
amounted 90.02%. The test DR increased to 92.10% after 
attaching the analysis of a flow in Ductus Venous. However, 
the highest DR was obtained when, apart from NT, MA, the 
DV-PIV — Pulsatility Index for Veins in Ductus Venosus was 
analyzed and then it amounted 81%. FPR amounted re-
spectively: 6.0 for NT + MA + BC, 5.8 for NT + MA + BC + the 
A-wave and 5.4 for NT+MA+BC+DV-PIV. The above results 
were obtained for the group risk 1:300.
Comparing mutually all groups of Trisomy 13 and 18 high 
risk, which is 1:300, 1:200, 1:100 and 1:50, the analysis indi-
cated similar dependencies. In all groups the test diagnostic 
sensitivity increased after taking into account the quantitative 
and qualitative assessment of a flow through DV. At the same 
time the number of FPR results decreased. It appeared that 
the most advantageous method was the consideration of the 
flow through a venous ductus together with the qualitative 
assessment of DV-PIV within the combined test, which was 
characterized by the highest DR = 89.30%. Additionally, the 
reduction of the level of Trisomy 18 and 13 risks to the level of 
1:200 let maintain similar sensitivity with the decrease of the 
percentage of FPR results in the analogical group and with the 
consideration of the qualitative assessment of DV-PIV to 3.5%.
Using statistical analysis sensitivity and specificity 
for tests that include measurements of NT, biochemistry, 
mother’s age — NT + BC + MA (Fig. 1) as well as for the 
test enlarged by the measurement of PIV — Pulsatility In-
dex in a Venous Duct — NT + BC + MA + DV-PIV (Fig. 2), 
the ROC were designated. Comparing both graphs for 
NT + BC + MA and NT + BC + MA + DV-PIV tests (Fig. 2), 
great diagnostic suitability of both tests was stated. How-
ever, it was noted that analyzing the Area Under Curve 
(AUC), the diagnostic suitability was bigger for the test 
extended by the DV-PIV (AUC respectively 0.9002 and 
0.9709). Therefore, the most favorable values were obtained 
for the test in which the combination of MA, NT, double 
test and DV-PIV, was taken into consideration. Tables 2– 
–4 shows comparison of Detection and False Positive Rates 
of Trisomies 18 and 13 using examined parameters.
DISCUSSION
During the diagnostic test planning, the highest DR, with 
a simultaneous reduction of FPR, is tried to be achieved. 
Table 1. Medians of outcomes of all examined and assessed 
parameters in both groups of normal and abnormal karyotypes
Healthy Trisomy 18 or 13 P
n 7239 57
CRL 62.70 59.50 0.0000
NT 1.70 3.90 0.0001
βHCG
MoM 1.05 0.51 0.0000
PAPP-A
MoM 0.96 0.34 0.0000
FHR 161.0 159.00 0.0000
MA 34.00 30.00 0.0000
DV PIV 1.00 1.80 0.0001
CRL — crown rump length; NT — nuchal translucency; FHR — fetal 
heart rate; βhCG — free subunit β of human Chorionic Gonadotropin; 
PAPP-A — pregnancy associates plasma protein-A; MoM — multiple of 
median, DV PIV — Ductus Venosus Pulsatility Index for Veins; MA — maternal 
age; p95 — 95 percentile
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Figure 1. ROC for NT + BC + MA
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Figure 2. ROC for NT + BC + MA + DVPIV
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Therefore, it is aimed at making the noninvasive tests sen-
sitive enough in order to provide the lowest number of 
patients selected to invasive examinations. The analysis 
of the blood flow in DV (as Trisomy 13 and 18 additional 
marker analyzed after obtaining the risk outcomes of a dis-
ease calculated according to NT and the double test) lets 
provide more precise selection of the chromosomal aber-
ration high risk group in the comparison with a method 
that is based only on the NT measurement and the double 
test analysis. It should be added that the flow assessment 
in DV includes two methods: the qualitative method — as-
sessment of the A wave shape (an atrial component) and 
the semi-quantitative method providing the PIV [3]. In the 
case of the qualitative assessment, the existence of the 
retrograde wave in DV is checked. In a situation when the 
A retrograde wave occurs during a heart contraction, in 80% 
of cases the fetus’s development can be normal but there 
exists an increased risk of the occurrence of chromosomal 
disorders, isolated heart defects or even death of a fetus 
[10]. Literature data show the 60% dependence between 
the occurrence of the A wave in DV and fetus’s heart defects 
[11]. In their scientific work Maiz and Nicolaides present even 
68% of such dependencies [12]. 
Effectiveness of Trisomy 13 and 18 screening calculated 
only on the basis of the NT measurement and the double test 
components lets detect about 91.8% of cases (DR = 91.8%) 
with the FPR about 2.2% [13]. Within our research in such 
a case we obtained DR — 90.02% and FPR — 6.0%. After 
considering the flow in DV, DR increased to 95.4% and FPR 
decreased to 1.3%. In the case of our results, DR and FPR 
amounted respectively: 94.81% and 5.4%. Similar outcomes 
for the assessment of NT and the double test were obtained 
by Kagan et al [14]: DR 91% for Trisomy 18 and 87% for Tri-
somy 13 but his FPR was significantly lower and it amounted 
0.2% for both aberrations. 
The qualitative assessment of the flow (assessment of 
the A-wave) lets obtain DR T13, 18 at the level of 92.10% with 
FPR amounting 5.8%. So, slightly better indicators than the 
Trisomy 13 and 18 risks assessment without the evaluation 
of the A wave in DV (DR 90.02% and FPR 6.0%) have been 
obtained. Results of our paper show that it is possible to 
gain even greater increase of DR to the amount of 94.81% 
with a simultaneous decrease of FPR to the value of 5.4% 
when PIV in DV included to the analysis. Similar results — the 
increase of DR and the decrease of FPR are also gained in the 
Trisomy 21 screening after including the assessment of the 
flow in DV. In such a case, Mainz and his partners obtained 
the following results: DR — 96%, FPR — 3%. 
CONCLUSIONS
Concluding, it should be noted that the quantita-
tive analysis of the flow — assessment of DV-PIV in the 
first trimester significantly influences the improvement 
of screening values focusing on Trisomy detection. This 
thesis is confirmed also by Zimmer and his partners’ [15] 
examinations, which indicate that for the test including 
NT + MA + BC + DV-PIV, the DR increased to 92% whereas 
for the test without DVPIV analysis of the factor amounted 
only 84%. Summing up, in comparison with the qualitative 
assessment of the flow in DV, our research indicates obtain-
ing more effective type of Trisomy 13 and 18 screening with 
the usage of the assessment of NT, double test and the 
quantitative analysis of DV flow.
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